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Background: Primary cilia are non-motile sensory cytoplasmic organelles that are involved in cell cycle progression.
Ultrastructurally, the primary cilium region is complex, with normal ciliogenesis progressing through five distinct
morphological stages in human astrocytes. Defects in early stages of ciliogenesis are key features of astrocytoma/
glioblastoma cell lines and provided the impetus for the current study which describes the morphology of primary
cilia in molecularly characterized human glioblastoma multiforme (GBM) tumors.
Methods: Seven surgically resected human GBM tissue samples were molecularly characterized according to
IDH1/2 mutation status, EGFR amplification status and MGMT promoter methylation status and were examined for
primary cilia expression and structure using indirect immunofluorescence and electron microscopy.
Results: We report for the first time that primary cilia are disrupted in the early stages of ciliogenesis in human
GBM tumors. We confirm that immature primary cilia and basal bodies/centrioles have aberrant ciliogenesis
characteristics including absent paired vesicles, misshaped/swollen vesicular hats, abnormal configuration of distal
appendages, and discontinuity of centriole microtubular blades. Additionally, the transition zone plate is able to
form in the absence of paired vesicles on the distal end of the basal body and when a cilium progresses beyond
the early stages of ciliogenesis, it has electron dense material clumped along the transition zone and a darkening of
the microtubules at the proximal end of the cilium.
Conclusions: Primary cilia play a role in a variety of human cancers. Previously primary cilia structure was perturbed
in cultured cell lines derived from astrocytomas/glioblastomas; however there was always some question as to
whether these findings were a cell culture phenomena. In this study we confirm that disruptions in ciliogenesis at
early stages do occur in GBM tumors and that these ultrastructural findings bear resemblance to those previously
observed in cell cultures. This is the first study to demonstrate that defects in cilia expression and function are a
true hallmark of GBM tumors and correlate with their unrestrained growth. A review of the current ultrastructural
profiles in the literature provides suggestions as to the best possible candidate protein that underlies defects in the
early stages of ciliogenesis within GBM tumors.
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Primary cilia are non-motile sensory cytoplasmic organ-
elles that have been implicated in signal transduction,
cell to cell communication, left and right pattern embry-
onic development, sensation of fluid flow, regulation of
calcium levels, mechanosensation, growth factor signaling
and cell cycle progression [1,2]. They are present in the
central nervous system and depletion of primary cilia in
pro-opiomelanocortin hypothalamic neurons have induced
hyperphagia [3,4]. Central nervous system primary cilia are
key organelles required for Sonic hedgehog signalling
(Shh) [5-8] where components Patched, Smoothened,
Suppressor of fused and Gli transcription factors con-
centrate in the primary cilium [9-11]. It is currently
thought that an intact primary cilium is required to en-
able proper Shh pathway function [12]. Subventricular
zone astrocytes extend their primary cilium into the
cerebral spinal fluid (CSF) suggesting they play a role in
sensing ion concentration, pH, osmolarity, and changes in
protein or glucose levels [13]. It is possible that astrocyte
primary cilia can sense concentrations of neurotransmit-
ters, growth factors, hormones, osmolarity, ions, pH and
fluid flow in the extracellular space and relay homeostatic
information (or lack thereof) to the centrosome.
Defects in the formation and/or function of primary
cilia underlie a variety of human diseases that impact
neurological development and are broadly referred to
as ciliopathies and include diseases such as Alström,
Bardet-Biedl, Joubert, Meckel-Gruber and oral-facial-digital
type 1 syndromes. Common neurological phenotypes
include obesity, ataxia and mental retardation [14]. The
expression and function of primary cilia has become a
focus of attention in a number of normal and malignant
cells and tissues but have not been characterized in
human glioblastoma tissue samples. Given that primary
cilia are linked to cell cycle regulation and progression,
several studies have suggested that primary cilia may
play a role in tumor formation [15,16].
Previously our group undertook a comparative investiga-
tion of primary cilia in cultured primary human astrocytes
and compared them to those found in five human astro-
cytoma/glioblastoma cell lines [17]. We demonstrated
that the primary cilium region in cultured astrocyte cells
is structurally complex, with ciliogenesis progressing
through five distinct stages (Figure 1), and included foci
for endocytosis-based signalling [17].
Further, we documented that in each of the five astro-
cytoma/glioblastoma cell lines studied (U-87 MG, T98G,
U-251 MG, U-373 MG, U-138 MG), fully formed primary
cilia are either expressed at a very low level, are com-
pletely absent or do not proceed through all the stages of
ciliogenesis [17]. In addition, we noted several defects in
the structure of astrocytoma/glioblastoma centrioles, in-
cluding abnormal length and appendage architecture, thatwere not observed in primary human astrocytes [17]. We
concluded that aberrant ciliogenesis is common in cells
derived from astrocytomas/glioblastomas and that this
deficiency likely contributes to the phenotype of these
malignant cells. These initial studies in astrocytoma/
glioblastoma cell lines indicate that defects in primary
cilium ciliogenesis do occur in glioblastoma cells and
provided the impetus for this current study which char-
acterizes the morphology of primary cilia and documents
ciliogenesis defects in molecularly characterized human
glioblastoma multiforme (GBM) tumors. Glioblastomas,
although relatively uncommon with an annual incidence
rate of 3–4 cases per 100,000 people, have dispropor-
tionately high morbidity and mortality rates with me-
dian survival pegged at 12–15 months [18,19]. Primary
glioblastomas typically occur in patients older than
50 years of age and are characterized by epidermal
growth factor receptor (EGFR) amplification and muta-
tions, loss of heterozygosity of chromosome 10q and other
abnormalities as reviewed in Wen and Kesari (2008) [20].
One of the most common defects in growth factor signal-
ling involves EGFR [21] and amplification occurs almost
exclusively in glioblastomas with 40-50% of patients con-
taining EGFR amplification [20]. Isocitrate dehydrogenase
(IDH) mutations are a strong predictor of a more
favourable prognosis and a highly selective molecular
marker for secondary glioblastomas [22]. Mutations of
genes encoding IDH1 and IDH2, as compared to no
mutations, are associated with younger age and a better
prognosis in adults with gliomas [23]. O6-methylguanine-
DNA methyltransferase (MGMT) promoter methylation
silences the MGMT gene, decreasing DNA repair activity
and increases the susceptibility of tumor cells to che-
motherapeutic agents [20]. Recently it was shown that
MGMT promoter methylation was associated with bet-
ter overall survival in patients with GBM regardless of
therapeutic intervention [24]. Given this burden of
disease, it is important to determine the degree to which
ciliogenesis is compromised in glioblastoma tumors as this
information will inform the identity of altered mecha-
nisms which may become targets for the development of
future treatments.
Our hypothesis was that primary cilia in human GBM
cells would be completely absent or show defects in the
early stages of ciliogenesis. Our primary objective was to
examine primary cilia expression and structure in human




Anonymized human brain tumor (GBM) tissue samples
and basic clinico-pathologic data were obtained through
the Clark Smith Brain Tumour and Tissue Bank at the
Figure 1 Primary ciliogenesis progresses through five morphologically distinct stages in human astrocytes. Key characteristics of each
stage are indicated with arrows. Paired lateral vesicles are prominent at the distal end of the basal body in Stage 1. Distal appendages are
triangular in appearance and reside at the distal end of the basal body (Stage 2). The paired lateral vesicles fuse to become a vesicular hat and
become stretched by the outgrowth of the primary cilium and can be seen progressing through stages 2 through 4. Stage 5 shows a mature
primary cilium with a surrounding cilium-pit. Used with permission from Moser et al. BMC Cancer 2009, 9:448, Figure 2A © BioMed Central.
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Calgary, AB (ethics approved for biobanking and previ-
ous patient consent granted at time of banking). Tissue
was used according to the policies of the institutional
review boards of Calgary Laboratory Services and the
Calgary Health Region Ethics Board. Further ethics
review and approval for this study (ID# E-23011) was
provided by the Conjoint Health Research Ethics Board
(University of Calgary, Calgary, AB).
GBM tissue samples
All samples were part of routine clinical care for diag-
nostic and treatment purposes and were designated as
excess material by the consulting and consenting neuro-
pathologist. Hematoxylin and eosin stained formalin-fixed
paraffin-embedded sections were reviewed by a neuro-
pathologist for confirmation of a diagnosis of high-grade
glioma (glioblastoma WHO grade IV) as per World Health
Organization criteria [18].
Molecular characterization of GBM tumors
Molecular characterization of IDH and EGFR was per-
formed by the clinical Molecular Diagnostics Labora-
tory at Calgary Laboratory Services on formalin-fixed
paraffin-embedded (FFPE) sections. Briefly, IDH1 and
IDH2 mutational analyses were performed using a
multiplexed SNaPshot® reaction and detection by capil-
lary electrophoresis [25]. Analysis of EGFR amplification
was performed by EGFR colorimetric in situ hybridization
using standard methods with the EGFR probe #84-1300
(Zymed Laboratories), and scored by a neuropathologist
as follows: ‘amplified EGFR’ indicates >10 signals/nucleus
in >80% of tumor cells and ‘not amplified’ indicates 2
signals/nucleus in tumor cells.
Antigen retrieval method (ARM)
Slides containing the FFPE tissue sections were deparaffi-
nised in xylene and passed through a graded ethanol series,
rinsed with cold tap water and transferred to a Coplin jar
on a hot plate containing a 100°C Tris-EDTA-Tween (w/v)solution (0.121% Tris HCl, 0.0379% EDTA, 0.05%
Tween-20, pH adjusted to 9.0). The sections were
boiled for 60 minutes and then allowed to reach room
temperature while remaining in the same solution. The
slides were washed in phosphate buffered saline (PBS)
for 10 minutes and processed for IIF.
Indirect immunofluorescence (IIF)
Formalin-fixed paraffin embedded tissue sections were
treated with the above ARM (section 3.4.). Cells were
blocked in 10% normal goat serum (NGS; Antibodies
Incorporated, Davis, CA) and 2% bovine serum albumin
(BSA; Sigma-Aldrich) for 30 minutes at room temperature
(RT) and incubated with primary antibodies at appropriate
working dilutions overnight at 4°C. Primary cilia were
marked by mouse anti-acetylated tubulin at 1:100 dilution
(Sigma, St. Louis, MO). After washing with PBS, cells were
incubated for 2 hours in a dark chamber with Alexa Fluor
(AF) 488 (green) secondary goat fluorochrome-conjugated
antibodies at 1:100 dilution (Invitrogen). Slides were
washed in several changes of PBS, cell nuclei counterstained
with 4’,6-diamidino-2-phenylindole (DAPI), mounted
in Vectashield (Vector Laboratories, Burlingame, CA)
and examined for IIF using a 100x objective on a Leica
DMRE microscope equipped with epifluorescence and
an Optronics camera. Appropriate IIF controls with no
primary antibody revealed no detectable bleed-through
between microscope filter sets.
Electron microscopy (EM)
Fresh GBM samples were immersed in a fixative con-
taining 3% glutaraldehyde in Millonig’s phosphate buffer
and stored at 4°C for 48 hours. Samples were immersed
post-fixation in 2% OsO4 for 20 minutes and then dehy-
drated in ethanol and infiltrated with Polybed 812 resin
(Polysciences Inc., Warrington, PA). Polymerization was
performed at 37°C for 24 hours. Silver-gray sections
were cut with an ultramicrotome (Leica) equipped with
a diamond knife, stained with uranyl acetate and lead
citrate and then examined in a H-700 Hitachi electron
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on standard sections. Approximately 500 cells were ex-
amined in each tissue sample.
Results
We examined both formalin-fixed paraffin embedded
(FFPE) and fresh-fixed tissue from seven cases of surgically
resected brain tumors diagnosed by neuropathologists as
grade IV glioblastoma/GBM using indirect immunofluores-
cence (IIF) and electron microscopy (EM), respectively.
The GBM tumors were molecularly characterized ac-
cording to IDH 1/2 mutation status, EGFR amplification
status and MGMT promoter status (Table 1). Our results
showed that 71% of GBM patients had amplified levels
of EGFR, 86% had no IDH1/2 mutations and 50% had
methylated MGMT promoters (Table 1).
We examined the biopsy tissue from each of the 7
patients by light and electron microscopy. IIF examination
of tissue from patient #1 showed typical primary cilia
(Figure 2, top inset). Similarly, ultrastructural examin-
ation revealed a normal basal body with a fully formed
mature primary cilium, consistent with normal morphology
(Figure 2 compared to Figure 1). The cilium-pit was well
defined (Figure 2) and the cilium contained well-formed
microtubules with normal spacing between doublets
(Figure 2, bottom inset). In addition, small vesicles were
seen along the cilium microtubules and interfacing with
the cilium-pit (Figure 2), which is consistent with previ-
ous findings that showed this is a site for endocytosis
based signalling [17].
The GBM tissue from patient #2 failed to show abun-
dant primary cilia by IIF. Ultrastructural examination
revealed cells with basal bodies reminiscent of stage 1
ciliogenesis, however there were no paired vesicles
present along the lateral sides of the distal end of the
basal body/transition zone as observed in longitudinal
and cross-sections (Figure 3A and inset compared to
Figure 1). In addition to missing paired vesicles, patient #2
had basal bodies that presented with abnormal, vertically
outstretched distal appendages (Figure 3B). Figure 3C
shows another example of an abnormal basal body withTable 1 Molecularly characterized grade IV glioblastoma GBM
Patient no. IDH 1/2
1 No mutations detected
2 No mutations detected
3 No mutations detected
4 IDH1 exon 4 R132H mutation detected; no mutation in
5 No mutations detected
6 No mutations detected
7 No mutations detectedabsent paired vesicles along the lateral sides of the distal
end of the basal body/transition zone. Interestingly, the
transition zone plate is present without the presence of
the vesicles which suggests that the vesicles do not need
to be present to allow the transition zone to form, but
need to be present to allow ciliogenesis to progress be-
yond stage 1. In one rare example, a primary cilium
which had progressed to stage 5 of ciliogenesis was
found (Figure 3D). On close examination, this cilium
displayed a disrupted ciliary membrane which was also
the site of cytoplasmic extrusions into the surrounding
environment (Figure 3D). These abnormal primary cilia
also have a dark pericentriolar material (PCM)-like collec-
tion of material clumped along the transition zone of the
primary cilium with darkening of the cilia microtubules at
the proximal end of the cilium shaft (Figure 3D).
The tissue from patient #3 revealed an absence of ma-
ture primary cilia by IIF and ultrastructural examination
showed that 70% of centrosome/basal body profiles were
at stage 1 while the remaining 30% of profiles examined
displayed stage 2/3 of ciliogenesis (Figure 4). Many of
the immature cilia contained electron dense material
along the cilium shaft (Figure 4 compared to Figure 1).
The stretched vesicular hat that is so prominent in normal
cells at stage 2/3 was irregular, thin and misshapen in
patient #3 GBM cells (Figure 4). The microtubules of the
cilium appear irregular, lack organization and do not
display the normal architectural characteristics of the
transition zone (Figure 4). There were no cilia in stages
4–5 observed for patient #3.
GBM tissue from patient #4 failed to display mature
primary cilium by IIF. Ultrastructurally, patient #4
expressed basal bodies that were similar to stage 1 with
a transition zone plate formed along the distal end
(Figure 5A compared to Figure 1). It is important to
note that in many of these electron microscope centro-
some/basal body profiles there was only 1 vesicle present
(as opposed to the normal 2 vesicles) at the distal end and
the vesicle was positioned directly above the transition zone
plate (as opposed to the normal lateral orientation beside
the transition zone plate) (Figure 5A). The architecture oftumors








Figure 2 Patient #1. GBM cells have an intact primary cilium. Electron
micrograph showing a mature primary cilium and basal body with a
well-formed cilium-pit (arrow) and endocytotic vesicles (short arrows).
Top inset, primary cilia as marked by acetylated tubulin (green) using
indirect immunofluorescence analysis. Bottom inset, cross section
through the axoneme of another cell. EM scale bar = 100 nm, IIF
scale bar = 7 μm.
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mal given their outstretched vertical appearance (Figure 5A)
as opposed to the normal horizontal appearance displayed
in Figure 1. Figure 5B, illustrates a discontinuity present in
one of the centriole microtubule blades, although this
centriole was 357 nm in length (Figure 5B) which falls
within normal parameters [17].
Samples from patient #5 did not show mature primary
cilia by IIF. Ultrastructural examination revealed either
basal bodies with an immature transition zone or profiles
similar to stage 1 (Figure 6 compared to Figure 1). The
transition zone was not visible in the electron micrograph
centrosome/basal body profiles from this patient and we
did not observe any paired vesicles similar to that seen in
patient #2 (Figure 6). There also appears to be minimal
PCM distributed in the cytoplasmic area surrounding the
basal body and centriole (Figure 6).
There were no observable primary cilia staining by
IIF in the GBM tissue from patient #6, although ultra-
structural examination showed cilia at multiple stages
(Figure 7). We observed profiles at stage 1 with a well-
defined plate within the transition zone lacking paired
laterally placed vesicles (Figure 7A). We observed
many cilia at stage 1 with either multiple irregular ab-
normally shaped vesicles formed at the distal end of
the basal body or 4 distinct vesicles above the plate
within the transition zone (Figure 7B). In the latter
case, distal appendages were absent. In rare cases, a
cilium with a short axoneme was detected (Figure 7C).
These cilia appeared to have a truncated cilium-pit so
that the distal end of the cilium is continuous with the
cytoplasm, a configuration reminiscent of a regressing
cilium [26].
GBM tissue from patient #7 also did not show any
primary cilia by IIF staining. Ultrastructurally, primary
ciliogenesis occurred in profiles to a maximum of stage 2
(Figure 8 compared to Figure 1). These cells had vesicular
hats that were misshaped and swollen (Figure 8A
and B) and had outstretched, vertical distal basal body
appendages (Figure 8B). These characteristics were similar
to those observed in other astrocytoma/glioblastoma
cell lines, particularly in U-373 MG and U-138 MG cells
(Figure 2B in [17]).
Discussion
The expression of a primary cilium relies on two main
events: 1) activation of ciliogenesis and 2) orderly pro-
gression through a series of developmental stages so that
a structurally and functionally competent mature cilium
is formed [27-29]. Our study illustrates that ciliogenesis
was activated in all the GBM samples examined but cilium
morphogenesis beyond stage 1 was rare in the majority of
tumors. These findings support our previous examination
of several astrocytoma/glioblastoma cell lines [17]. Thus,
Figure 3 Patient #2. GBM cells are halted at stage 1 of ciliogenesis with rare cells progressing to stage 5. (A) Basal body and abnormal stage 1
cilium with absent paired lateral vesicles. Inset cross section through the transition zone from another cell. (B) Basal body and abnormal stage 1
cilium with vertically outstretched distal appendages and no vesicles. (C) Basal body with clear transition zone and abnormal stage 1 cilium with
absent vesicles. (D) Rare occurrence of a primary cilium at stage 5 with abnormal destruction of the cilium-pit with cytoplasmic extrusion, darkened
microtubules at proximal end of cilium and electron dense collection of material at the transition zone. EM scale bars = 500 nm.
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express a similar defect or set of defects that targets the
earliest stages of ciliogenesis and does not inhibit the cells
ability to proliferate.
These findings are compatible with previous studies of
melanoma, renal cell carcinoma and pancreatic cancer,
which found that primary cilia loss was independent of
Ki67 staining (cell proliferation marker) suggesting that
cilia loss is not the result of altered cellular proliferationrates but rather may be due to aberrations in another
mechanism that is inherent to ciliogenesis [30-32]. Yang
and colleagues (2013) recently showed that cell cycle-
related kinase (CCRK) and its substrate intestinal cell
kinase inhibited ciliogenesis in a glioblastoma cell line
[33]. Specifically, they showed that dysregulated high
levels of CCRK are present in U-251 MG glioblastoma
cells whereby knockdown of CCRK led to the formation
of primary cilia indicating that CCRK depletion restored
Figure 4 Patient #3. GBM cells are halted at stage 3 of ciliogenesis
and display electron dense material clustered along the cilium shaft
(arrow heads) and an irregular vesicular hat (arrows). EM
scale bar = 100 nm.
Figure 6 Patient #5. GBM cells were characterized by abnormal
primary cilia that were halted at or before stage 1 of ciliogenesis
with no evidence of paired vesicles or a transition zone plate. EM
scale bar = 250 nm.
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that the inhibition of ciliogenesis by over-expression of
CCRK in U-251 MG glioblastoma cells promoted cell pro-
liferation capacity [33].
From our ultrastructural studies in astrocytoma/glio-
blastoma cell lines and GBM tumor tissues it is interest-
ing to note that profiles occasionally displayed centriole/
basal bodies with structural abnormalities (i.e. altered
length or microtubule integrity). This suggests that it is
possible for such structural alterations to be tolerated by
the cycling cell, perhaps by being repaired, or that these
defects underlie further aberrant cancer cell behaviour.
It is important to note that in the majority of previously
published studies, IIF alone was used to evaluate cilio-
genesis status. This technique alone does not allow for
the precise identification or characterization of the
earliest stages of ciliogenesis. Thus, truncated cilia
such as that seen in a few patients within our study
may be more common that previously indicated. Our
ultrastructural data not only reveals a defect in early
ciliogenesis but also shows that this defect specificallyFigure 5 Patient #4. GBM cells were characterized by (A) primary cilia tha
above the transition plate and abnormal distal appendages and (B) breakaaffects the initial elaboration of the distal surface of the
basal body and its ability to associate with Golgi derived
vesicles. There have been a number of proteins shown to
act at the distal end of the basal body, particularly at the
distal appendage region, and they include; Cep170 [34],
ninein [8,35], ɛ-tubulin [36], cenexin/ODF2 [37] (likely
cenexin1 [38]) and by association Rab8a [39], centriolin/
Cep110 [8,40], Cep164 [41] and Cep123 [42] reviewed in
[1]. For example, in neuronal primary cilia, B9-C2 con-
taining proteins have been shown to collect at the base of
the primary cilium in the transition zone [43-47] and
physically interact and with ciliary protein localization
[48] (and reviewed in [49]). One B9-C2 family gene in par-
ticular named Stumpy (or B9d2) is required for mammalian
ciliogenesis where knockout mutants displayed near-
complete loss of neuronal primary cilia with remaining cilia
displaying dysmorphic stump-like ultrastructures [43].
Of particular interest, a distal appendage protein, Cep
123, has recently been shown to be required for initiationt were halted at stage 1 of ciliogenesis with a single vesicle present
ges in the basal body/centriole microtubules. EM scale bars = 100 nm.
Figure 7 Patient #6. GBM cells were characterized by abnormal primary cilia at (A, B) stage 1/2 and (C) 4/5 of ciliogenesis with either absent
lateral vesicles, aberrant supernumerary vesicles along the length of the transition zone plate or abrupt cessation of the cilium shaft. EM
scale bars = 100 nm.
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the mother centriole with a ciliary vesicle [42]. Sillibourne
and colleagues (2013) showed that Cep123 is required for
assembly of a primary cilium but not the maintenance of
the axoneme in human retinal pigment epithelial (RPE1)
cells [42]. Depletion of Cep123 using Cep 123 siRNA
perturbed ciliary vesicle formation at the distal end of
the basal body which suggests that distal appendage
proteins are critical for progression of cilia beyond the
early stages of ciliogenesis [42]. These knockdown stud-
ies are captured in Figure 6B by Sillibourne et al. (2013)
[42] and are very similar in appearance to the abnormal
early stages of ciliogenesis seen in our GBM tumors.
Given this high degree of ultrastructural similarity,
Cep123 may be the best candidate to explain the defects
we observed in GBM tumors. Although a review of the
glioblastoma literature does not highlight Cep123 as
being defective in patients with GBM tumors, our studysuggests that it is a reasonable target for future expression
studies and ultrastructural analysis in GBM tumors.
Limitations of the current study are small sample size
and lack of normal brain tissue for comparison. Given
the small incidence of malignant gliomas per year, we
collected samples over a 5 year period and eliminated
those samples that were not grade IV glioblastomas/
GBM. To respect the ethics of collection of normal
human brain tissue from our patients, we compared the
GBM patient results to those previously established in
normal human astrocyte cells that were used between
passages 3–5 in culture [17]. Although 10 grids were ex-
amined for each patient sample, there were noticeable
differences between tumor samples in terms of cellularity
and patient heterogeneity. It is important to emphasize
that this is a complex mixture of cells and extracellular
matrixof GBM brain tissue and that some cell types are
ciliated whereas others are not ciliated. Because of the
Figure 8 Patient #7. GBM cells were characterized by abnormal
primary cilia at stage 2 of ciliogenesis with (A) swollen vesicular hats
(B) misshaped vesicular hats and abnormal distal basal body
appendages. EM scale bars = 100 nm.
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identify all the cells which have the potential to undergo
ciliogenesis. When we do see profiles, we can quantitate
the number of cells undergoing abnormal ciliogenesis (in-
cluding profiles at stages 3/4/5) which is summarized as
follows. Patient #1: 20 cells with profiles, 2 cells with nor-
mal cilia, 0 cells with abnormal cilia. Patient #2: 9 cells
with profiles, 0 cells with normal cilia, 2 cells with ab-
normal cilia. Patient #3: 20 cells with profiles, 0 cells
with normal cilia, 2 cells with abnormal cilia. Patient
#4: 22 cells with profiles, 0 cells with normal cilia, 0 cells
with abnormal cilia. Patient #5: 20 cells with profiles, 0 cells
with normal cilia, 0 cells with abnormal cilia. Patient #6: 30
cells with profiles, 0 cells with normal cilia, 3 cells with
abnormal cilia. Patient #7: 15 cells with profiles, 0 cells with
normal cilia, 0 cells with abnormal cilia. Taken together,
only one patient expressed morphologically normal cilia.
As a whole, we did see the same types of abnormalities in
the early stages of ciliogenesis amongst tumor samples
which suggests that early ciliogenesis defects are a gen-
eralized problem in GBM tumors. In summary, we can
say that the large majority of grade 4 glioblastoma/
astrocytomas (i.e. GBM tumors) are likely to expressabnormal immature primary cilia suggesting that this defect
may be a hallmark of GBMs. We have not detected a clear
correlation between abnormal ciliogenesis and the 3 main
molecular characterizations examined in these patient sam-
ples. It must be kept in mind that our patient sample size
may not be sufficient to reveal correlations with molecular
markers and this might require a larger study.
In summary, we found that ciliogenesis is activated in
GBM tumors but the normal development of a mature
cilium is perturbed at early stages of ciliogenesis. The
aberrant ultrastructural profiles observed in our survey
of GBM tumors and a review of the current ultrastruc-
tural profiles present in the literature suggest the possi-
bility that at present the best possible candidate protein
underlying defects in the early stages of ciliogenesis
within GBM tumors might involve Cep123.
Conclusions
The major finding of this report is that primary cilio-
genesis is disrupted at an early stage in the majority of
human GBM tumors. This finding is important for
several reasons. First, these results confirm astrocytoma/
glioblastoma cell culture data. Second, it indicates that
defects in ciliogenesis are a hallmark of GBM tumor
pathology and provides impetus for further study of the
relationship between primary cilium defects and other
brain tumors such as astrocytoma, oligodendroglioma
and medulloblastoma. Third, it provides further evidence
that the early stages of ciliogenesis are a critical time in
the process of ciliogenesis, thus narrowing the number of
target proteins that may underlie these defects. Fourth, it
catalogues and describes the key basal body/cilium-related
ultrastructural abnormalities that are common between
GBM tumors. The ultrastructural description of this study
informs which proteins are involved in early ciliogenesis
defects and identifies candidates that are currently in the
literature. In future, it will be important to elucidate which
specific proteins are involved in this critical time period
and whether alterations in their expression can restore
ciliogenesis and thus restore cell cycle control.
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